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1 Introduction 
 
1.1 The role of the endogenous opioids in neuroendocrine regulation 
 
1.1.1 The families of opioid neuropeptides; chemical nature, distribution and receptor 
preference 
 
The opioids have a prominent and versatile impact on numerous physiological parameters. 
Their analgesic action, the tolerance and dependence they evoke and their side effects have 
been in the centre of countless studies aiming at the discovery of the ideal "pain-killer" in the 
past few decades. It is also of vital importance to clearly establish the whole spectra of the 
effects and feasible side effects of the synthetic opiates and the new endogenous opioid 
peptides and their analogues to outline their pharmacological potential. 
Until the seventies, the physiological background of the diverse actions of morphine, 
the major alkaloid of the opium poppy (Papaver somniferum) was barely clarified31. 
Numerous potent, synthetic compounds have been identified, but only with the 
characterisation of the enkephalins58 did it become clear that it is the endogenous opioid 
peptides that target the opiate receptors in physiological circumstances.  
It is now known that there exist at least five families of endogenous opioids. The first 
one described in 1975 was that of the enkephalins. Their precursor peptide proenkephalin 
contains 6 copies of Met-enkephalin and one copy of Leu-enkephalin sequences. They are 
widely distributed in the brain and the peripheral nervous system, where they function as 
neurotransmitters and modulators. They are also expressed in the endocrine, reproductive and 
immune system31. Some longer derivatives of these family (like MERF) show especially high 
expression in the central nervous system (CNS)130 and appear to possess distinct 
biochemical10,161 properties. 
The dynorphins (dynorphin-A, dynorphin-B, -neo-endorphin and some shorter 
related peptides) derive from prodynorphin. They are also found in neural, endocrine and 
reproductive tissues, although their concentrations are lower. They are also presumed to 
function as neurotransmitters in the brain and the spinal cord74. 
The third family consists of -endorphin and its shorter derivatives, which are 
synthetized as part of the pro-opiomelanocortin (POMC). POMC products are found in both 
central and peripheral tissues. In the CNS they are expressed in the cells of the arcuate 
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nucleus of the hypothalamus and the nucleus tractus solitarius of the medulla. Much higher 
concentrations are present in the anterior and intermediate lobes of the pituitary and some 
amount is expressed by the reproductive and immune systems36,140.  
The fourth family is the nociceptin peptide family, product of a reverse-
pharmacology125. The first described heptadecapeptide orphanin FQ represents the long-
sought ligand of a heterotrimeric G protein-coupled receptor that proved very similar in 
sequence to the opioid receptors and named opioid receptor like 1 (ORL1)100. Nociceptin109 
and its receptor99 are quite evenly distributed in the CNS. Both the peptide97,101,118 and the 
receptor99 are also expressed at the periphery in peripheral ganglia, smooth muscles, the 
endocrine and the immune system. 
Last but not least the endomorphins (EMs) should be mentioned as the putative 
endogenous ligands of the -opioid receptor. They were isolated from the bovine brain167. 
Besides MERF our efforts were concentrated on revealing their behavioural and endocrine 
actions. 
The five families of endogenous opioid peptides act on 4 classes of opioid receptors for 
which associated function has been well defined (Table 1.). The are designated as , ,  and 
ORL1 receptors. Moreover, three further opioid receptor classes have been proposed in the past 
few years. They were named ,  and  receptors, but the functional role of these receptors has 
not beeen established yet, and they now not considered to be opioid in nature ( or do not seem 
to represent distinct pharmacological entities (, )31. The -receptors, selectively targeted by 
morphine and the EMs, described in the chronic spinal cord model91, mediate analgesia, miosis, 
bradycardia and hypothermia. The subtypes (123) are responsible for different actions 
since analgesia is mediated by the 1, while respiratory depression by the 2 receptor. The -
receptors, described in the same model, are activated ketocyclazocine and the dynorphins appear 
their endogenous ligands. They are responsible for sedation, depression of flexor reflexes and as 
many as four subtypes have been identified with radioligand binding assays27. The  receptors86 
mediate analgesia and activate several motor paradigms30; they appear to bind preferentially the 
enkephalins3. The ORL1 is endowed with supraspinal pronociceptive/anti-opioid properties. It 
has not yet been found to precipitate withdrawal in morphine-tolerant rats nor does it elicit 
motivational effects, suggesting it lacks abuse liability97. Although the -receptor is not a 
typical opiate receptor since it does not show the classical stereospecificity3 and the receptor 
activation can not be reversed by naloxone31, some “non-opioid” actions (CNS activation, mania, 
pupillary dilatation, tachypnea, tachycardia) of the opioid peptides seem to be transmitted by this 
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receptor. 
The functional assays for studying the opioid receptors revealed that it is the adenylate-
cyclase and the intracellular cAMP that are affected by the opioids predominantly. Both the 
and the-receptors show a remarkable inhibition of adenylate cyclase26,31. Further they also 
appear to activate potassium conductance and inhibit the voltage-dependent inward calcium 
current56,105. The -138,160 and ORL149 receptors exhibit the same second messenger profile, 
therefore their distinct pharmacological spectra can be attributed to their different distribution 
pattern. 
 
1.1.1.1 The endomorphins; the characteristics of the recently discovered endogenous -opioid 
ligands 
In spite of the fact that they differ considerably in structure from previously known endogenous 
opioids167 (Fig. 1.) radioreceptor binding assays have revealed that these peptides possess high 
affinity and selectivity for the -opioid receptors47. It has been concluded that they might be 
endogenous ligands for the morphine receptors, and they were therefore named endomorphin-
1 (EM1) and endomorphin-2 (EM2)167. 
The EMs are widely and densely distributed throughout the rat brain (posterior hypothalamic 
nuclei, locus coeruleus and amygdala), as demonstrated by immunocytochemical studies93. 
Several physiological effects of the EMs have already been described, too. These results 
reflect that these opioid peptides have distinct pharmacological profiles, which is in some 
cases markedly different from that of morphine. They exert a profound spinal analgesic 
effect146,167, similarly to morphine, but they even antagonize neuropathic pain, whereas 
morphine seems ineffective123. Further, EM1, like morphine63,106, has anxiolytic and 
orexigenic properties5, while its cardiovascular activity25 appears to differ from that of 
morphine40. These functional differences may result from the differences in selectivity of the 
EMs and morphine as concerns the opioid receptor subtypes: the EMs display high selectivity 
to the -opioid receptor, while morphine binds to both the -and the -receptors47,103,141,166-168. 
Further, the EMs and morphine prefer different molecular forms of the opioid receptor135, 
and only the EMs exhibits an ability to internalize their receptor21. Taken together the 
widespread distribution of them in the CNS and the aforementioned physiological phenomena 
suggests that they might belong to the endogenous peptide mediators of nociceptive, 
behavioural and autonomous processes, in which opioid regulation plays a well-established 
and critical role3. 
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1.1.1.2 The characteristics of the enkephalin related peptide MERF 
Met5-enkephalin-Arg6-Phe7 (MERF) (Fig. 2) is one of the most widespread and abundantly 
expressed enkephalin derivative in the CNS. Altough it was first isolated from bovine adrenal 
glands and striatal extracts145 later proved to be widely distributed in the CNS of different 
vertebrates75,130,149. Despite its high expression and unique and rather ambigouos 
pharmacological profile, only a few publications have dealt with its physiological function: a 
chimeric peptide based on MERF displayed prominent antinociceptive characteristics51 and 
MERF was also demonstrated to have immunocyte excitatory properties150. Besides, 
contradictory data are still available regarding its affinity for the different subtypes of opioid 
receptors. In vitro receptor binding assays either suggested -receptor mediation76 or 
demonstrated predominant 2 signaling10,161. Substantial (50 % in rat cerebrum) naloxone 
resistant and moderate  2 binding was also found in both amphibians and rodents10,11,14,162. 
Biological assays revealed naloxone-reversible antinociception59 and antitussive effects70. 
 
1.1.2 The role of the opioid neuropeptides in the regulation of behaviour and the 
hypothalamic-pituitary-adrenal axis 
 
The role of the opioid system in the regulation of locomotion8 is well characterized. 
Earlier studies demonstrated that opioid peptides influence the locomotor activity through the 
  and -opioid receptors: the  and -opioid receptors mediate locomotor 
hyperactivity98,157, while selective -receptor agonists decrease linear locomotion156. 
However, the results of behavioural experiments have been found to depend strongly on the 
strain43, the sex78, the time60 and the dose80,142. Further behavioural phenomena are also under 
opioid control. The effects of morphine on rearing and grooming are strongly dose- and time-
related presumably in consequence of different involvements of opioid receptor 
subtypes60,72,117. Further it is well-established that opioid peptides (mainly enkephalins) 
participate in the intricate subcortical neuronal networks that regulate locomotion44 (Fig. 3). 
Participation of an opiate mechanism in the corticosterone response previously has 
been demonstrated too: acute administration of morphine activated the HPA axis in the rat66 
and drew attention to the examination of the role of the opiates in the control of stress 
response113. Further studies indicated that the action of the opioids appears to be species-
dependent. In humans, they seem to inhibit HPA activation28, whereas in rodents their effect 
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is more probably stimulatory87,144. Nevertheless, in both species opioids are the most 
important mediators of stress-induced analgesia2,88. 
 
1.2 The purpose of our experiments 
 
The purpose of the present study was to examine the effects of EMs on behavioural responses, 
and to compare the actions of this endogenous opioid ligand to those of morphine.  
In the present work, to further scrutinize the effects of EM1 on the HPA axis, 
adrenocorticotropic hormone (ACTH) release from isolated anterior pituitary slices and the 
corticosterone secretion of adrenal slices were measured after EM1 treatment in an in vitro 
perifusion system. The following experiments were designed to shed light on the mediation of 
the neuroendocrine responses brought about by EM1.  
Corticotropin-releasing hormone (CRH) plays a very important role in the activation of the 
HPA axis158, and has a marked impact on behavioural phenomena, too. It was reported that 
microinfusion of CRH into the paraventricular nucleus (PVN) induces locomotion102, and an 
increase in rearing has also been described in several publications143,159. In the present 
experiments, therefore the CRH antagonist -helical CRH9-41 was applied before the 
administration of the EMs, in order to clarify its possible role in mediation of the EMs-evoked 
neuroendocrinological responses.  
As previous studies have indicated that opiates might evoke locomotor hyperactivity through 
the secretion of dopamine in the nigrostriatal and mesolimbic dopaminergic system16, the 
effects of intraperitoneally (ip.) administered haloperidol on the motor activation elicited by 
EM1 were tested. Since different opioids appear to exert rather diverse effects on the 
subcortical motor neurons90,132, the action of EM1 on the basal and stimulated dopamine 
release from striatal slices were also measured in an in vitro superfusion system. Histological 
studies have demonstrated an interaction between the dopaminergic and opiatergic neurons in 
the hypothalamus84, and therefore the effects of haloperidol pretreatment on the endocrine 
response evoked by EM1 were tested, too. 
Several publications have demonstrated that the gaseous neurotransmitter nitric oxide (NO) 
(Fig. 4.) plays an indispensable role in the mediation of the physiological actions of 
morphine48, but conflicting data are available regarding the function of NO in morphine-
evoked HPA activation18,83. Recent data have provided evidence of the role of NO in the 
transmission of the vasodilatory action of the EMs24, though Rialas et al.126 demonstrated that 
EMs are unable to release NO through the 3-opioid receptor. Therefore, to reconcile these 
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conflicting data and to investigate whether (beside vasodilation) NO plays a more 
comprehensive role in the mediation of the actions of the EMs, the effects of the NOS inhibitor 
NG-nitro-L-arginine (L-NNArg) on the neuroendocrine responses evoked by EM1 were also 
examined. 
Since MERF was isolated in the highest concentration from locomotor centres and the 
hypothalamus in the CNS116,119,130,145, we set out to shed light on its possible role in 
neuroendocrine control and to elucidate the mediation of its action. The purpose of the present 
study was to test the effect of MERF on the HPA axis and open-field parameters to observe 
exploration and stress-related behaviour77. Square crossing (horizontal activity), rearing 
(vertical activity) and grooming were monitored as separate paradigms, since previous 
publications demonstrated that they can change independently and different neurotransmitters 
might be involved in their control73,77,139. 
Because in vitro data have suggested both opioid and non-opioid binding10,11, with the 
help of the non-selective opioid antagonist naloxone we tried to estimate the significance of 
naloxone sensitive signaling in the in vivo actions of MERF. As the heptapeptide is the 
proposed endogenous ligand for the receptors in the rat brain6,10, the -antagonist nor-
binaltorphimine (nor-BNI) was also used to investigate the role of -mediation in the 
neuroendocrine effects of MERF. 
Previous studies have indicated that opioids might act on locomotive behaviour and 
the HPA system indirectly, through the secretion of other mediators. Several publications 
suggested, that the nigrostriatal and mesolimbic dopaminergic circuitries might relay the 
locomotor hyperactivity elicited by morphine16,39,122, and histological studies pointed out an 
interaction between the opioid and the dopaminergic system in the hypothalamus41,84. 
Accordingly, the effect of haloperidol pretreatment on the open-field behaviour and HPA 
activation brought about by MERF, and the action of this opioid neuropeptide on the basal 
and stimulated dopamine release of striatal slices were tested. Recent publications have also 
substantiated that CRH, one of the most potent regulators of stress-related behavioural96,102 
and hormonal processes158, might mediate the neuroendocrine responses to opioid 
peptides19,20. For this reason, animals were pretreated with -helical CRH9-41 to investigate 
the involvement of CRH transmission in the behavioural and hormonal responses elicited by 
MERF. 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 The tested peptides 
 The EMs were either obtained from the Institute of Biochemistry of the Biological 
Research Centre, Hungarian Academy of Sciences, Szeged (they were synthesized as 
described by Tömböly et al.153) or purchased from Sigma;  
 MERF was synthesized by solid phase peptide synthesis using N--butoxycarbonyl (Boc) 
strategy161 in the Institute of Biochemistry (Biological Research Centre, Hungarian 
Academy of Sciences, Szeged). 
 
2.1.2 Substances used in the in vivo experiments; the materials used for corticosterone assay 
 CRH antagonist -helical CRH9-41. 
 Haloperidol (Richter, Budapest, Hungary)  
 L-NNArg (Sigma) 
 Naloxone hydrochloride (Sigma) 
 Nor-BNI-dihydrochloride (Sigma) 
 Saline (sodium chloride inj. of 0.9 %, Biogal, Hungary) 
 Ethyl alcohol, methylene chloride and sulfuric acid of analytical grade (Reanal, Budapest) 
for corticosterone assay 
 
2.1.3 Substances used in the in vitro experiments 
 The components used for the Krebs’ buffer preparation: NaCl, KCl, MgSO4, NaHCO3, 
glucose, KH2PO4 and CaCl2 of analytical grade (Reanal, Hungary) 
 (3H)dopamine (Amersham Pharmacia Biotech UK) 
 Mixture of 5% CO2 and 95% O2 for continuous gassing 
 Scintillation fluid (Ultima Gold, Packard) 
 
2.2 Animals 
 
Male CFLP mice of an outbred strain (LATI, Gödöllő, Hungary) weighing 25-35 g were used at 
the age of 5 weeks. The animals were kept in their homecages at a constant room temperature on 
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a standard illumination schedule with 12-h light and 12-h dark periods (lights on from 6.00 a.m.). 
Commercial food and tap water were available ad libitum. The animals were kept and handled 
during the experiments in accordance with the instructions of the University of Szeged Ethical 
Committee for the Protection of Animals in Research. 
 
2.3 In vivo experiments 
 
2.3.1 Surgery 
The mice were allowed a minimum of 1 week to acclimatize before surgery. Subsequently, 
the animals were implanted with a polyethylene cannula (3 mm long; 0.4 mm in inner and 1.8 
mm in outer diameter) aimed at the right lateral cerebral ventricle under Nembutal (35 mg/kg, 
ip.) anaesthesia. The stereotaxic coordinates were 0.5 mm posterior and 0.5 mm lateral to the 
bregma, and 3 mm deep from the dural surface, and the cannula was secured to the skull with 
acrylate. The mice were used after a recovery period of at least 5 days. All experiments were 
carried out between 8:00 and 10:00 a.m. At the end of the experiments, the correct position 
and the permeability of the cannulae was checked. In the behavioural studies, each mouse was 
sacrificed under pentobarbital anaesthesia, and the heads were also collected after 
decapitation in the endocrinological experiments. Methylene blue was injected via the 
implanted cannula and the brains were then dissected. Only data from animals exhibiting the 
diffusion of methylene blue in all the ventricles were included in the statistical evaluation. 
 
2.3.2 Behavioural testing, the open-field apparatus 
The mice were removed from their home cages and placed in the centre of a square, wooden, 
white-coloured open-field box consisting of 49 squares (5 x 5 cm each). The standard source of 
illumnation was a 60 W bulb from 80 cm. The horizontal locomotor activity was characterized 
by the total number of squares crossed during a 3-min test session (square crossing). The vertical 
locomotor activity was characterized by the number of rearings (standing on the hind legs). 
Groomings (face washing, forepaw licking and head stroking) were also observed. 
 
2.3.3 Corticosterone assay 
The mice were decapitated 30 min after treatment, and trunk blood was collected in heparinized tubes. 
The plasma corticosterone level was determined by fluorescence assay124,170. 
 
2.3.4 Experimental protocols 
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2.3.4.1 Investigation of the action of the endomorphins or MERF on open-field behaviour and 
the activation of the HPA axis 
Different doses of EM1 (from 250 ng to 5 g), EM2 (from 250 ng to 1 g) or MERF (from 500 
ng to 5 g) dissolved in 0.9 % saline was administered intracerebroventricularly (icv.) in a 
volume of 2 l into conscious mice with a Hamilton microsyringe over 30 s, immobilization 
of the animals being avoided during handling. Control mice received saline alone. Thirty min 
after EMs administration the animals were subjected to behavioural tests or were sacrificed to 
obtain blood samples for the corticosterone assay. 
 
2.3.4.2 Combined treatment with peptide (-helical CRH9-41), opiate (naloxone and nor-BNI) 
or non-opiate (haloperidol and L-NNArg) antagonists and the opioid neuropeptides 
For this experimental setting, the animals were subjected to combined treatment with an antagonist 
and an opioid peptide. L-NNArg, haloperidol and -helical CRH9-41 were tested with EM1, -
helical CRH9-41 with EM2, while naloxone hydrochloride, nor-BNI-dihydrochloride and -
helical CRH9-41 with MERF. The opiate antagonists, the CRH antagonist and L-NNArg were 
dissolved in 0.9% saline and injected icv. in a volume of 2 l, while haloperidol (dissolved in 
0.9% saline) was administered ip. in a volume of 0.3 ml. The opiate receptor blockers were 
applied in equimolar concentration with a view to finding the most effective dose. The dose of 
the non-opiate antagonist was the concentration that had proved most effective in our previous 
experiments, and per se does not affect the endocrine and behavioural paradigms64,115,152. Thirty 
min after the antagonist pretreatment, the animals were treated icv. with the dose of the EMs or 
MERF that had proved to be most effective in the previous protocol. Control mice received 
saline alone. Thirty min after the peptide administration, the animals were subjected to 
behavioural tests or were decapitated to obtain blood samples for the corticosterone assay. 
 
2.4 In vitro experiments 
 
2.4.1 The superfusion system 
 
2.4.1.1 Investigation of the action of EM1 and MERF on the basal and stimulated dopamine 
release of striatal slices 
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The mice were decapitated, the brains were rapidly removed and the striata were dissected in a 
Petri dish filled with ice-cold Krebs solution. The dissected tissue was cut with a McIlwain tissue 
chopper and slices of 200-300 m were produced. The slices were preincubated for 30 min in 5 
ml of Krebs solution as an incubation medium, submerged in a water-bath at 37 °C and gassed 
through a single-use needle (30 G; 0.3 x 13) with a mixture of 5% CO2 and 95% O2; the pH was 
maintained at 7.4. The slices were labelled with (3H)dopamine during the preincubation: the 
medium was supplemented with 0.15 mM (3H) dopamine (spec. act. 14 Ci/mmol). The 
superfusion apparatus consisted of four cylindrical perspex chambers (Experimetria Ltd, 
Budapest, Hungary). The upper half was fitted with an inlet and the lower half with an outlet, 
and a circular piece of nylon net was placed just below the outlet and above the inlet. When fitted 
together, the halves enclosed a compartment of about 150 l (5 mm long and 5 mm in 
diameter).Gold electrodes were attached to both the upper and the lower half-chamber and the 
electrodes were connected to an ST-02 stimulator (Experimetria Ltd, Budapest, Hungary). After 
preincubation, the labelled slices were transferred to the superfusion chambers and washed for 45 
min, using a multichannel peristaltic pump (Gilson Minipuls 2), to allow tissue equilibrium and 
to remove the excess radioactivity from the labelled samples. Before transfer of the slices into the 
chambers, all the tubing and the lower half were filled with oxygenized superfusion medium, and 
during the washing-out phase care was taken that all air bubbles came out from the chambers. 
The chambers were superfused with Krebs buffer at a rate of 200 l/min from a reservoir kept at 
37 °C and gassed with a mixture of 5% CO2 and 95 % O2. In the antagonist studies with EM1, L-
NNArg was added to the buffer during the initial washing-out period. Afterwards, the slices were 
superfused for 30 min and the superfusates were collected in tubes in 2-min fractions by means 
of a multichannel fraction collector (Gilson FC 203B). Chambers I and II were superfused with 
Krebs solution, and chambers III and IV with Krebs solution containing EM1 (10 M) or MERF 
(1 or 5 . Two samples were taken as a baseline and electrical stimulation was then delivered 
to chambers II and IV for 2 min. The stimuli consisted of square-wave impulses (voltage: 25 V, 
pulse length: 25 ms, frequency: 2 Hz). At the end of the experiment, the slices were solubilized 
in 200 l Krebs solution, using an ultrasonic homogenizer (Branson, Sonifier 250). The 
radioactivity in the fractions and the homogenized tissue samples was measured with a liquid 
scintillation spectrometer (Tri-carb 2100TR, Packard) after addition of the appropriate 
scintillation fluid (3 ml Ultima Gold). The fractional release was calculated as a percentage of the 
radioactivity present in the slices at the sample collection time. 
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2.4.2 The perifusion system 
2.4.2.1 Investigation of the action of EM1 on the ACTH release of pituitary and 
corticosterone secretion of adrenal slices 
 
We used the in vitro system described by Saffran and Schally131 as a starting-point in developing 
our experimental design. Mice were sacrificed by decapitation and the adrenals and the pituitary 
were removed. The adrenals were cleaned from the adhering fat and capsule and the posterior 
lobe of the pituitary was dissected and discarded. The adrenals and the anterior lobe were 
weighed on a micro torsion balance and were immediately transferred to separate Petri dishes 
containing ice-cold, Krebs solution (113 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 25 mM 
NaHCO3, 11.5 mM glucose, 1.2 mM KH2PO4, 2.5 mM CaCl2, pH=7.4) as incubation medium. 
Both the adrenals and the pituitaries were rapidly cut with a McIlwain tissue chopper and slices 
of 200-300 m were produced and placed in separate plastic flasks. The flasks, containing 5 ml 
incubation medium, were submerged in a water-bath at 37 °C and constantly and gently gassed 
through a single-use needle (30 G; 0.3 x 13) with a mixture of 5% CO2 and 95% O2; the pH was 
maintained at 7.4. The slices were preincubated for 1 hour, at the end of which the medium was 
sucked out and discarded. In 5 ml of fresh medium, 10 M EM1 or the medium alone as a 
control was added. The samples were incubated for half an hour, after which 200 l aliquots of 
the medium were transferred for ACTH or corticosterone determination. The ACTH 
concentrations of the samples were determined by RIA: ELSA-ACTH (CIS-bio International, 
France) is a solid-phase two-site immunoradiometric assay (ACTH radiolabelled with iodine 
125). Corticosterone concentrations were determined by fluorescence assay. 
 
2.5 Statistical analysis 
Values are presented as means S.E.M. Statistical analysis of the results was performed by 
analysis of variance (ANOVA). For the perifusion experiments and to evaluate the dose-
response curves of the opioid peptides one-way ANOVA was applied followed by Tukey’s 
post hoc test for multiple comparisons with unequal cell size (Spjotvoll-Stoline), when test 
prerequisites were fulfilled. If the test of homogeneity of variances had not been passed 
nonparametric ANOVA on ranks (Kruskal-Wallis) was performed followed by Dunn’s test 
for multiple comparison. Two-way ANOVA was applied for the antagonist studies and two-
way ANOVA with repeated measures for the superfusion experiments to detect overall 
treatment effect and to evaluate treatment x treatment or time x treatment interactions. For 
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pairwise multiple comparisons Bonferroni’s method was carried out. A probability level of 
0.05 was accepted as indicating a statistically significant difference. 
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RESULTS 
3. 1. The actions of the EMs 
 
3.1.1. Effects of the EMs on behaviour and the HPA system 
 
3.1.1.1 Effect of the EMs on open-field parameters 
The administration of EM1 (0.25-5 g) into the right lateral brain ventricle caused a 
significant increase in locomotor activity (Fig. 5). A dose of 0.5 g increased the number of 
squares explored (F(5, 58), p<0.01 vs. control) but the most effective dose was 1 g (p<0.001 
vs. the control). The higher doses of the peptide (2 and 5 g) did not give rise to further 
increases in locomotion (p=0.075 and 0.08 vs. the control, respectively). The tetrapeptide 
dose (1 g) that led to the most significant response in locomotor activity also elevated the 
number of rearings (p<0.001 vs. the control) (Fig. 5). As concerns grooming, EM1 elicited 
only a tendency to an increase, which did not prove to be statistically significant (Table 2).  
 
 Different doses of EM2 (0.25-1 g) also caused significant changes in the behavioural 
tests (Fig. 6). A dose of 0.25 g increased the number of squares explored (F(3, 48) = 5.97, 
p<0.05 vs. control), but the most effective dose was 0.5 g (p<0.01 vs. the control). A higher 
dose of the peptide (1 g) did not give rise to a further increase in locomotion (p=0.28 vs. the 
control). The tetrapeptide dose (0.25 g) that led to a significant response in locomotor 
activity failed to elevate the number of rearings (p=0.1 vs. the control) (Fig. 6), but higher 
doses (0.5 and 1 g) elicited significant increases in the number of rearings (p<0.05). In the 
case of grooming, no difference was observed between the control and the EM2-treated group 
(Table 3). 
 
3.1.1.2 Effect of the EMs on basal corticosterone release 
EM1 induced a significant increase in plasma corticosterone level. A dose of 5 g elevated the 
corticosterone level by 157% as compared to the control (F(3, 35)=4.48, p<0.05) (Fig. 7).  
 
EM2 in a dose of 0.25 g elevated the corticosterone level by 142% as compared to the 
control, though this response was not statistically significant. (F(3, 44)=4.03, p=0.2 vs. the control). A 
higher dose (0.5 g) of EM2 elevated the corticosterone level in a statistically significant 
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manner (p<0.05), but further elevation of the dose (1 g) did not result in an additional 
increase (p=0.99 vs. the control) (Fig. 8). 
 
3.1.1.3 Effect of the receptor antagonists (-helical CRF9-41, haloperidol and L-NNArg) on the 
behavioural responses evoked by the EMs 
Preliminary administration of the CRH antagonist -helical CRH9-41 (1 g) completely abolished 
the increases in both locomotion (F(3, 46), p<0.001 vs. EM1) and the number of rearings 
elicited by EM1 (p<0.05 vs. EM1) (Fig. 9).  
 
 
The CRH antagonist pretreatment also diminished the EM2-induced locomotor response in 
a dose-dependent manner. The dose of 1 g furnished only a tendency to attenuation, but a 
higher dose (2 g) brought about a statistically significant inhibition (F(5, 73)=8.6; p<0.01 vs. 
EM2) (Fig. 10). The dose of 1 g of -helical CRH9-41 inhibited the rearing activity induced 
by EM2 in a significant manner (p<0.05 vs. EM2) and the higher dose of the CRH antagonist 
completely abolished the effect of EM2 (p<0.001 vs. EM2) (Fig. 10). 
 Haloperidol pretreatment inhibited both the square crossing (p<0.05 for 
haloperidol+EM1 vs. EM1) and rearing (p<0.05 for haloperidol+EM1 vs. EM1) brought 
about by EM1 (F1, 32=28.80; p<0.0001 for square crossing and F1, 32=17.22; p<0.001 for 
rearing vs. the control) (Fig. 11). L-NNArg also mitigated the behavioural (p<0.05 for square 
crossing and p<0.05 for rearing for L-NNArg+EM1 vs. EM1) effects of EM1 (Fig. 12). 
 
3.1.1.4 Effect of the receptor antagonists (-helical CRF9-41, haloperidol and L-
NNArg) on the endocrine responses evoked by the EMs 
The corticosterone response induced by either EM1 (Fig. 13) or EM2 (Fig. 14) was also 
inhibited by pretreatment with -helical CRH9-41 ((F(3, 24 )=7.96 , p<0.05 vs. EM1), F(3, 47) = 
10.88 , p < 0.01 vs. EM2). 
While L-NNArg significantly inhibited the corticosterone release evoked by EM1 
(p<0.05 for L-NNArg+EM1 vs. EM1) (Fig. 15), the pretreatment with haloperidol proved to 
be completely ineffective (Table 4). 
 
 
3.1.2 Effects of EM1 on the transmitter release of isolated tissue samples 
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3.1.2.1 Effect of EM1 on the corticosterone secretion of adrenal slices and the ACTH release 
of pituitary slices 
The EM1 treatment did not have a statistically significant impact on the corticosterone 
secretion from the adrenal slices (F1, 22=0.32; p=0.58 vs. control) and moderately inhibited the 
ACTH release from the pituitary slices (F1, 6=21.2; p<0.01) (Fig. 16). 
 
3.1.2.2 Effect of EM1 on the basal and stimulated dopamine release of striatal slices and the 
effect of L-NNArg on the EM evoked response 
In the superfusion experiments, all channels displayed stable baseline with minimal leakage of 
dopamine (2-3 %/min) after the washing-out period, reflecting the viability of the slices. 
Electric impulse elicited an approximately 300 % increase in dopamine release. Although 
EM1 did not influence the basal release from the striatal slices, it considerably augmented the 
dopamine release evoked by electric impulses (F3, 288=4.25; p<0.05 vs. control). L-NNArg 
alone did not have an impact on dopamine release but the effect of EM1 was significantly 
inhibited by L-NNArg pretreatment (p<0.05 for L-NNArg+EM1 vs. EM1) (Fig. 17). 
 
3.2. The actions of MERF 
 
3.2.1. Effects of MERF on behaviour and the HPA system 
 
3.2.1.1 Effect of MERF on open-field parameters 
MERF elicited an increase in square crossing at 1, 2 and 5 g doses (ANOVA, F4, 47 = 8.5, 
p<0.001; Tukey’s post hoc, p<0.005, p<0.001 and p<0.0005, respectively) (Fig. 18). An 
increase in rearing activity was also brought about by MERF, although only the highest dose 
proved to be effective (ANOVA, F4, 47 = 3.5, p<0.05; Tukey’s post hoc, p<0.05) (Fig. 18). In 
contrast, MERF did not have a considerable impact on grooming (Table 5). 
 
3.2.1.2 Effect of MERF on basal corticosterone release 
MERF evoked an almost 100 % elevation of plasma corticosterone level at the dose of 5 g 
(ANOVA on ranks, Kruskal-Wallis H=14.5; p<0.01; Dunn’s pairwise comparison, p<0.05) 
(Fig. 19). 
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3.2.1.3 Effect of the receptor antagonists (naloxone, nor-binaltorphimine (nor-BNI), -helical 
CRF9-41, and haloperidol) on the behavioural responses evoked by MERF 
Naloxone inhibited the MERF-induced increases in square crossing and rearing (Fig. 20) at 
the highest antagonist dose (two-way ANOVA, overall effect of antagonist treatment F2, 
80=4.9 for square crossing, p<0.01; treatment x treatment interaction F2, 80=5.8 for square 
crossing and 6.7 for rearing, p<0.005; Bonferroni’s pairwise comparison p<0.05 vs. MERF). 
On the other hand, nor-BNI exhibited only a tendency to attenuation of square crossing, 
which did not prove statistically significant and did not affect the number of rearings (Table 
6). 
 
 Haloperidol produced a marked inhibition of the MERF-evoked increase in square 
crossing (two-way ANOVA, overall effect of haloperidol treatment F1, 35=27.3, p<0.001; 
treatment x treatment interaction F1, 35=14.0, p<0.001; Bonferroni’s test, p<0.05 vs. MERF) 
(Fig. 21). The MERF-induced rearing activity was also diminished by haloperidol 
pretreatment (two-way ANOVA, overall effect of haloperidol treatment F1, 35=8.3, p<0.01; 
treatment x treatment interaction F1, 35=4.8, p<0.05; Bonferroni’s test, p<0.05 vs. MERF) (Fig. 
21). 
 The increase in square crossing was attenuated by the preadministration of the CRH 
antagonist (two-way ANOVA, overall effect of antagonist treatment F1, 31=20.8, p<0.001; 
treatment x treatment interaction F1, 31=4.3, p<0.05; Bonferroni’s test, p<0.05 vs. MERF) (Fig. 
22). Applying the CRH antagonist similar inhibition was observed in the MERF–induced 
rearing response (two-way ANOVA, treatment x treatment interaction F1, 31=6.8, p<0.05; 
Bonferroni’s test, p<0.05 vs. MERF) (Fig. 22). 
 
3.2.1.4 Effect of the receptor antagonists (naloxone, nor-binaltorphimine (nor-BNI), -helical 
CRF9-41, and haloperidol) on the endocrine responses evoked by MERF 
The HPA response evoked by MERF was almost completely abolished by both 0.4 and 4.0 g 
naloxone (two-way ANOVA, overall effect of antagonist treatment F3, 59=7.6, p<0.005; 
treatment x treatment interaction F3, 59=5.9, p<0.005; Bonferroni’s test, p<0.05 vs. MERF) 
(Fig. 23). Also, a clear inhibition of MERF-induced HPA activation was observed with a dose 
of 10 g of the -antagonist (two-way ANOVA, overall effect of antagonist treatment F3, 84= 
3.9, p<0.05; Bonferroni’s test, p<0.05 vs. MERF) (Fig. 24). 
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 While the dopamine antagonist turned out to be ineffective on the HPA response 
elicited by MERF (Table 7), the HPA response evoked by MERF was completely abolished 
by the CRH antagonist (two-way ANOVA, overall effect of antagonist treatment F1, 38=6.0, 
p<0.05; Bonferroni’s test, p<0.05 vs. MERF) (Fig. 25). 
 
3.2.2 Effect of MERF on the basal and stimulated dopamine release of striatal slices 
The electric impulse elicited an approximately 300 % increase in dopamine release as 
compared with baseline (two-way ANOVA with repeated measures, overall effect of electric 
impulse F1, 20=16.5, p<0.001; time x electric impulse interaction F15, 300=24.5, p<0.0001). 
Neither dose of MERF had a significant impact on the spontaneous or the electric impulse-
evoked dopamine release (Fig. 26). 
4 Discussion 
 
 The present experiments clearly demonstrate that intracerebroventricularly (icv.) 
administered EMs and MERF lead to a marked activation of square crossing and rearing. At a 
molar basis MERF (2 g  2 nmol) evoked a similar response as EM1 (1 g  2 nmol). On 
the other hand EM2 evoked even more prominent behavioural actions than EM1 since 
considerably smaller concentrations (0.4-0.8 nmol) of EM2 elicited the analogous response.  
Our findings are in agreement with those of earlier studies that showed opioids to have 
a pronounced impact on neuroendocrinological processes113. However, the results of 
behavioural experiments have been found to depend strongly on the strain43, the sex78 and the 
receptor preference of the substance32,61,85. Additionally, different opioids produce actions that 
differ in temporal course60 and display a very strong dose-dependence80,142. Outside the 
neonatal period62, the effects of the selective  agonists, on both locomotion and rearing are 
inhibitory61,80,156. In contrast, morphine activates locomotion8, possibly acting in the ventral 
tegmental area68 and in the nucleus accumbens55. Previous studies have suggested that this 
process is presumably mediated by  and  receptors, since both selective  and  agonists 
induce locomotor hyperactivity85. Rearing is also enhanced by morphine72;  and  mediation 
also play important roles in this phenomenon32. Our results, when the receptor specificity of 
the EMs is taken into consideration, indicate that opioids mainly stimulate locomotion and 
rearing through the -opioid receptor. 
 Both EMs exhibited a bell-shaped dose-response curve with a downturn phase at 
higher doses, and the effective concentration range proved to be narrow. Such a phenomenon 
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has already been described with regard to the effects of other neuropeptides104,152, the EMs163 
and their derivatives78. This feature may reflect functional antagonism in post-receptorial 
signal transduction120 such as receptor phosphorylation by a G protein-coupled receptor 
kinase42. The inhibitory action of less-specific receptors57 at higher concentrations or the 
postsynaptic down-regulation of the receptor synthesis7 also might be taken into 
consideration. 
Recently it has been established that, after the formalin test, morphine brought about 
locomotor hyperactivity exhibiting a downturn phase at the highest dose142, whereas the EMs 
did not. Since the doses (1-10 g) of the EMs tested in the aforementioned study142 were 
almost one order of magnitude higher than the effective concentrations in our experiments 
(0,25-1 g) and the EMs possess a conspicuously narrow bell-shaped dose-response curve, 
revealing that in the case of EM2 the response evoked by the dose of 1 g was not different 
from the control, our data appear to be consistent at the doses tested with the results of 
Soignier et al.142. 
Our behavioural findings with MERF corroborates the results of earlier histological 
studies. As previous publications revealed abundant expression of MERF in the striatum of 
different species119, and its marked release from striatal slices116 our findings suggest that the 
heptapeptide might function as an endogenous opioid regulator of locomotive behaviour. This 
hypothesis is in line with previous histological data demonstrating enkephalinergic 
projections to form prominent subsets of both the striatonigral and striatopallidal pathways44. 
Both behavioural phenomena were diminished dose-dependently by the nonselective opioid 
antagonist naloxone suggesting, that at least in these processes, non-opioid binding does not 
play a significant role. On the other hand, nor-BNI did not have a considerable impact on the 
behavioural responses elicited by MERF, and it is worth-mentioning that nor-BNI alone 
displayed a tendency to activate the motor parameters. It implies that mediation does not 
play a significant role in the behavioural actions of MERF, and together with the results of 
Kuzmin et al.80, assigns a tonic inhibitory function to the  receptors in the regulation of 
motor parameters. 
Neither the EMs nor MERF elicited a significant alteration in grooming in the doses 
that brought about marked changes in both locomotion and rearing. Opiates seems to exert 
quite ambiguous effects on grooming, depending on the dose and the testing schedule60,117. 
Despite the contradictory nature of the available data, it appears that in the setting of acute 
administration, grooming is activated through the  receptors9,157. Since the EMs in the given 
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dose-range prefers the  subtype of the opioid receptor family133,134, our data support the 
hypothesis that opioid mediation does not play a significant role in the mediation of 
grooming. Although, previous experiments revealed78, that topical administration of an 
enzyme-resistant analogue, D-Pro2-EM-2 in a dose of 50 g into the ventrolateral 
periaqueductal gray, evoked a sex-dependent activation of grooming in the rat. This 
difference can be attributed not only to the structural, but also to species differences, or may 
reflect a pharmacological rather than a physiological action of this endomorphin derivative. 
Further, as circumstantial evidence, our data reinforce the hypothesis proposed by in vitro 
studies6,10, that inspite of being an enkephalin derivative, MERF behaves as a  or  rather 
than a agonist. 
 Centrally administered EMs and MERF also stimulated corticosterone secretion in our 
experiments. This is in harmony with previous studies revealing a prominent but species-
specific action of morphine and other opiates on the HPA axis113. Their action, in rodents, is 
predominantly stimulatory18-20, although reflects species and age-related 
differences19,20,29,46,66,83,95,148,. Similar species-related differences have been observed 
regarding the action of opiates on locomotive behaviour79 and food intake54, which might be 
related to differences between rats and mice in the expression and function of the opioid 
receptors165.  
 Earlier studies also pointed out that the opioid system and the stress response are 
strongly interwoven in another respect, too. It is the opioid peptides that mediate the 
decreased pain responsiveness upon stress. Cold-swim stress13, food deprivation94 and 
footshock1 all produce naloxone reversible analgesia. Such a relief was demonstrated to 
depend on the release of such endogenous opioids as -endorphin and the enkephalins2,129. 
The two phenomena might form a reinforcing positive feed-back loop at the beginning of the 
stress reaction that, increasing pain-threshold, helps the individual to cope with the stressful 
condition. 
Both naloxone and nor-BNI pretreatment inhibited the MERF evoked HPA activation. 
Present findings are consistent with those of previous studies18,23,112,151 indicating that 
andreceptor mediation activates the HPA system. Since the hypothalamus displays high 
expression of MERF119, our data support the hypothesis that this endogenous  and 2-opioid 
ligand might function as a physiological regulator of stress response, and are in agreement 
with previous data, which demonstrated the selective -agonist MR 2034 to stimulate CRH 
secretion111. 
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On the other hand, in the perifusion experiments EM1 did not influence the 
corticosterone secretion from the adrenal slices and slightly inhibited the ACTH secretion 
from the pituitary slices, which argues for the central action of the EMs-evoked HPA 
activation. The hypothalamic site of action of the opioids is also suggested by literature data. 
They do not activate the corticotrop cells in the pituitary164, fail to elicit direct adrenocortical 
activation in vivo34 and have rather an inhibitory impact on the corticosterone release from 
dispersed adrenal cells50. Morphine has also been demonstrated to act on the hypothalamus 
increasing its CRH content in vivo147 and to activate the CRH release from isolated 
hypothalami17. These findings are in agreement with the antagonist studies: in our 
experiments -helical CRH9-41 preatreatment completely abolished the endomorphin evoked 
corticosterone release19,20 and previous publications revealed that the HPA activation elicited 
by opioid peptides could be blocked by CRH antiserum preatreatment111. Consequently, the 
effect of the EMS on the HPA axis is likely to be mediated through the action of CRH, and 
other neuropeptides such as vasopressin12, neurotensin110 or thyrotropin-releasing hormone137 
do not seem to play a relevant role in the HPA response to the EMs. This finding is supported 
by previous data35 that demonstrated EM1 to inhibit the vasopressin and oxytocin neurones in 
the hypothalamus. The CRH antagonist also significantly attenuated the corticosterone release 
brought about by MERF, which results argue for the central action of the heptapeptide, too. 
However, as complete inhibition was not observed, the involvement of other activators of 
ACTH secretion (vasopressin and neuropeptide Y) cannot be excluded in the action of MERF 
on the HPA axis. Taking the distribution93,116,119 and receptor specificity6,10,47,76,167 of the EMs 
and MERF into account our results suggest that they might act as endogenous opioid 
regulators of the HPA axis. 
Not only the endocrinological but also the behavioural responses evoked by the the 
opioid peptides could be completely blocked by -helical CRH9-41 preatreatment. Since 
increase in locomotion may reflect not only exploration but also fear, our results might 
demonstrate that the opioid-induced anxiety (mediated by CRH release) can evoke the 
increase in locomotion and acts a stress paradigm, too. However, in our experiments the 
differences between the effective opioid doses on behaviour (0.25-1 g) and on plasma 
corticosterone (0.5-5 g) might suggest that different neural mechanisms might be involved in 
these actions, despite the fact that both effects can be attenuated or blocked by the CRH 
antagonist. Indeed, several publications showed that CRH evokes a characteristic locomotor 
activating response through its action on the PVN96,102 and the limbic system81. The 
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behavioural actions of CRH appear to be independent of its effect on the pituitary-adrenal axis 
as demonstrated by both indirect15 and direct38 evidence: neither hypophysectomy38 nor 
dexamethasone blockade15 of the HPA axis influences the locomotor response evoked by 
CRH. The opioids presumably induce CRH release at a hypothalamic level and this action can 
be inhibited by the antagonist at a pituitary level. On the other hand the behavioural effects of 
them may also be elicited in extrahypothalamic structures. Nevertheless the behavioural 
response also appears to be mediated by CRH, as it could be inhibited by the CRH antagonist. 
The EM2-evoked activation of locomotion, rearing and corticosterone release is quite 
similar to that of EM119. However, some differences are worth mentioning. The 
concentrations of EM2 that evoked the analogous response were lower than those of EM1 in 
all studies. Moreover, while the actions of EM1 could be completely antagonized by 1 g 
CRH antagonist19, twofold concentration was needed to abolish the EM2-evoked responses. 
Similar differences in effectiveness have been reported by other authors. EM1 seems to exert 
more profound effects in the tail-flick and hot-plate responses154, while EM2 appears to be 
more effective in the formalin test142 and its cardiorespiratory effects33 are more pronounced 
than those of EM1. Histological studies have revealed that their distributional patterns in the 
CNS differ too93: EM1-like immunoreactivity is more widely and densely distributed in the 
brain, whereas EM2 is more prominent in the spinal cord. The dyscrepancy in their 
physiological actions can be explained by the putative differences in the signal transduction of 
EMs. EM1 and EM2 apparently activate different subtypes of the -opioid receptors: the 
actions of EM2 seem to be transmitted by the 1 or the heroin/morphine-6eta-glucuronide 
subtype of the  opioid receptor, while the effects of EM1 appear to be confined some 
isoforms of the 2 receptor108,133,134; neither of them interact with the 3 subtype. The G-
protein profiles activated by EM1 or EM2 also appear to differ135: the analgesic response 
evoked by both EM1 and EM2 could be inhibited by the impairment of proteins Gi1 and Gi3 
while the impairment of protein Gi2 blocked only the action of EM2. Moreover, there is 
strong evidence that EM1 activates only the -opioid receptors, whereas after initial -opioid 
activation, EM2 may elicit the release of Met-enkephalin and/or dynorphin154. 
 Haloperidol pretreatment completely abolished the EM- or MERF-induced increase in 
both square crossing and the number of rearings suggesting their behavioural actions are 
mediated through dopaminergic transmission. The present finding corroborates the results of 
previous studies demonstrating the dopamine-dependent motor actions of opiates68, and the 
crucial and species-specific79 role of the ventral and dorsal striatum in relaying the action of 
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opiates on locomotion169. Further, by in vitro studies, the locomotor action of opiates has been 
demonstrated to depend on the dopamine concentration of the mesolimbic and nigrostriatal 
structures89. However, the apparent dyscrepancies between the effects of the EMs or MERF 
on the striatal dopamine release suggest that their in vivo actions might imply different 
molecular mechanisms. While EM1 appear to facilitate dopamine release or alternatively 
decrease dopamine reuptake, the negative results of the superfusion studies with MERF cast 
doubt on its direct action on the dopaminergic terminals in the striatum; such finding can be 
explained by the differences in the receptor specificity of EM1108,133,134 and MERF6,10,76. EM1 
might act presynaptically on the axons of the nigrostriatal pathway, while the MERF positive 
neurons may belong to the opiatergic projections of the striatonigral and striatopallidal 
pathways44, and they regulate dopaminergic transmission in the substantia nigra52 rather than 
in the caudate-putamen. Besides, compelling evidence is emerging, that MERF may also 
stimulate another monoaminergic circuitry, the mesolimbic dopaminergic cells, through the 
inhibition of GABAergic67,82 and serotonergic121 transmission37, or through the activation of 
CRH release19,20 (Fig. 27.). Nonetheless, it is worth-mentioning that MERF is more 
susceptible to the action of inactivating peptidases10 than the EMs153, which might also 
Fig. 27. The role of EM1 and MERF in the control of the subcortical motor system 
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explain the conspicous difference in the effectiveness of these opioids. Therefore, further 
experiments with the help of peptidase inhibitors might help to shed light on the direct action 
of MERF on nigrostriatal axon terminals. 
Although conflicting data are available regarding the role of dopaminergic mediation 
in the HPA response4,65, the histological evidence suggests an interaction between the opioid 
and the dopaminergic neurons in the PVN84. However, in our experiments, the HPA 
activation evoked by neither the EMs nor MERF was inhibited by haloperidol pretreatment, 
which lends support to the view resulting from previous data92 that the actions of opiates on 
the HPA system do not involve dopaminergic transmission92. 
 Both the behavioural and endocrine responses elicited by EM1 proved to be especially 
sensitive to L-NNArg pretreatment. Further, L-NNArg successfully inhibited the facilitatory 
effect of EM1 on the stimulated dopamine release in the superfusion studies. These data are in 
harmony with the findings of previous authors, clearly establishing that NO and/or the 
glutamate-NO-cGMP system114 mediates numerous actions of opiates45. Further, our data also 
broaden the concept of NO mediation in the action of the EMs. It appears not only that the 
cardiovascular actions of the EMs are transmitted by NO24, but also that a general role can be 
 NO 
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assigned to NO in the mediation of the actions of these opioid tetrapeptides. Moreover, the 
opioid-NOS system might represent the physiological source of those NO which has been 
established to stimulate locomotion22 and striatal c-Fos expression53. 
 Our results suggest that L-NNArg plays neither an activatory nor an inhibitory role in 
the basal secretion of corticosterone, which result is in harmony with numerous in vitro71 and 
in vivo data128. On the other hand, it proved to inhibit the corticosterone release elicited by 
EM1. Hence, the present findings in agreement with previous publications, assign a critical 
role to NO in the mediation of HPA activation. Literature data point to an intricate 
mechanism, which governs the release of NO in the stress response, which seems strongly 
dependent on the nature of the stressor. Different neural pathways and mediator profiles 
belonging to various stress stimuli appear to have strikingly different impacts on the release of 
this gaseous transmitter. NO proved to stimulate the stress response to physico-emotional 
stimuli155, while it displayed a robust inhibition of the HPA activation elicited by immune 
signals127. When our results are taken into consideration, it can be hypothesized that the EMs 
Fig 28. The mediation of the action of EM1 on the HPA axis 
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and/or other endogenous opioids released by physical stressors, such as electric foot-
shocks107, might activate the hypothalamic NOS155, which leads to the subsequent activation 
of the HPA system. This idea is strongly supported by literature data demonstrating the 
stimulatory action of the NO-cGMP system on hypothalamic CRH release71 (Fig. 28).  
In conclusion, present data signify that both the EMs and MERF might function as a 
physiological regulator of the HPA axis and behaviour. Our findings confirm the hypothesis 
that the  and -receptors may relay the actions of MERF but argues against the role of non-
opioid mediation in the actions of the heptapeptide. CRH proved to be an important mediator 
of both the endocrine and behavioural actions of the peptides, and the experiments with 
haloperidol strengthen the hypothesis that CRH release might lead to the subsequent 
activation of the mesolimbic dopaminergic structures. This hypothesis is corroborated by 
previous studies demonstrating that the locomotor activating properties of CRH strongly 
depend on the dopamine metabolism in the nucleus accumbens69. However, on the basis of 
the in vitro data only the EMs appear to act directly on the striatal dopamine release, and 
according to the results of the endocrinological studies, the HPA activation evoked by the 
opioids does not involve dopaminergic transmission. Our results also raise the possibility that 
the EM-NO-CRH system might be one of the prominent stimulators of the HPA axis, and a 
similar neurotransmitter cascade might be involved in the stress-related motor activation 
elicited by the EMs.  
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5 SUMMARY 
 
In the present experiments, the role of the EMs and MERF in the control of open-field 
paradigms and the HPA response has been established. The main findings of the presented 
studies: 
 
1. Both the EMs and MERF after icv. administration elicited remarkable horizontal and 
vertical responses in the open-field system. Their action was dose-dependent and in the case 
of the EMs the dose-response curve displayed a characteristic bell-shape. 
2. Similarly, these opioids activated the HPA axis in a dose-dependent manner and also, at a 
molar basis, like in the behavioural experiments, EM2 proved to be more effective than EM1 
and MERF. 
3. Naloxone and nor-BNI pretreatment significantly and dose-dependently attenuated the 
endocrine response evoked by MERF while in the behavioural experiements only naloxone 
proved to be effective. These data point to the importance of -mediation in the MERF 
evoked HPA activation, while -mediation appear to prevail in the behavioural responses. 
4. The previous icv. application of the CRH antagonist -helical CRH9-41 inhibited both the 
behavioural and the HPA response induced by the opioid peptides. As regards EM1 these data 
with the findings of the perifusion experiments argues for the central site of action of the 
EMs. 
5. Haloperidol pretreatment completely abolished the behavioural responses evoked by MERF 
or EM1 but proved to be ineffective on the endocrine responses elicited by the opioids. 
6. Both the in vivo and in vivo effects of EM1 could be inhibited by L-NNArg pretreatment, 
which findings support the view that NO might mediate the actions of the EMs and other 
opiates. 
We hope that our data have provided further evidence for the importance of opioid 
neuropeptides in the complex and flexible regulation of the HPA axis and behaviour. Our 
findings revealed the receptor preference of MERF in vivo and outlined the spectra of 
mediators involved in the transmission of the neuroendocrine actions of MERF and the EMs. 
In a further set of experiements we intend to broaden the scope of our studies and try 
to clarifiy the action of these opiates and their analogues (like Tyr-D-Ala-Gly-Phe-D-Nle-
Arg-Phe of MERF) on the regulation of further behavioural (spontaneous locomotion) and 
autonomic processes (thermoregulation, circulation) in a telemetric system. 
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